Investment Thesis

. A price level below $50 or a significant negative regulatory event could trigger a reevaluation of the position.

Competitive Moat

primarily through its intangible assets, notably its brand reputation and proprietary technology in CGM systems. This advantage is bolstered by regulatory approvals, which create high entry barriers for potential competitors, and a loyal customer base that relies on its products for effective diabetes management. Over the next 5-10 years, this moat is likely to remain durable, although rising competition from established players like Abbott and Medtronic poses a threat, particularly if they enhance their product offerings or reduce prices.

Growth Engine

Future revenue growth for DexCom is anchored in a substantial total addressable market (TAM) driven by the increasing prevalence of diabetes, projected to rise significantly as lifestyle factors contribute to higher incidence rates. The company is actively expanding its market share through geographic expansion and the rollout of innovative products, including the next-generation G7 CGM system. Furthermore, the integration of real-time CGM data into third-party applications enhances its market reach, indicating a trajectory of organic growth as opposed to reliance on acquisitions.